Evaluation of Cancer Antigen 125 and as Biomarkers and Therapeutic Targets
Advisor(s)
Dr. Sowmya Anjur; Illinois Mathematics and Science Academy
Discipline
Medical and Health Sciences
Start Date
21-4-2021 10:05 AM
End Date
21-4-2021 10:20 AM
Abstract
Ovarian cancer has the fifth lowest survival rate by cancer type at 48% after 5 years, however in earlier stages ovarian cancer has a lower mortality rate. This makes the use of biomarkers useful for tracking the progression of ovarian cancer and as a therapeutic target. In this research project two biomarkers were studied, CA-125 and MR-1, to form a hypothesis on which biomarker was better at tracking Ovarian cancer. A literature review was done to get an understanding of the biomarkers and open-source data was used to analyze the expression of the biomarkers in Ovarian Cancer. Data from CA-125 showed a correlation of higher CA-125 expression with a higher probability of Ovarian cancer. While current data and literature on MR-1 show it is a potential biomarker and target, however this data is still limited. While CA-125 is overexpressed in Ovarian cancer, it is also overexpressed in other common diseases as well, which limits its abilities as a diagnostic. While MR-1, while overexpressed in multiple cancer types, may show to be a better diagnostic.
Evaluation of Cancer Antigen 125 and as Biomarkers and Therapeutic Targets
Ovarian cancer has the fifth lowest survival rate by cancer type at 48% after 5 years, however in earlier stages ovarian cancer has a lower mortality rate. This makes the use of biomarkers useful for tracking the progression of ovarian cancer and as a therapeutic target. In this research project two biomarkers were studied, CA-125 and MR-1, to form a hypothesis on which biomarker was better at tracking Ovarian cancer. A literature review was done to get an understanding of the biomarkers and open-source data was used to analyze the expression of the biomarkers in Ovarian Cancer. Data from CA-125 showed a correlation of higher CA-125 expression with a higher probability of Ovarian cancer. While current data and literature on MR-1 show it is a potential biomarker and target, however this data is still limited. While CA-125 is overexpressed in Ovarian cancer, it is also overexpressed in other common diseases as well, which limits its abilities as a diagnostic. While MR-1, while overexpressed in multiple cancer types, may show to be a better diagnostic.